Yahoo Italia Ricerca nel Web

Risultati di ricerca

1. Notizie più importanti

   • Investing

     Telefonata di presentazione: Ocugen riporta i progressi e i dati finanziari del secondo trimestre 2024

     Avviso esplicito sui rischi: Il trading degli strumenti finanziari e/o di criptovalute comporta alti rischi, compreso quello di perdere in parte, o totalmente, l’importo dell’investimento, e potrebbe non essere adatto a tutti gli investitori. I prezzi ...

     2 giorni fa

   • 

     The Motley Fool on MSN.com

     Ocugen (OCGN) Q2 2024 Earnings Call Transcript

     3 giorni fa

   • 

     MarketWatch

     Ocugen Inc. stock falls Friday, underperforms market

     2 giorni fa

   • MyChesCo on MSN.com

     Ocugen Reports Q2 2024 Financial Results and Business Update

     2 giorni fa

   • Yahoo Finance

     Ocugen Provides Business Update with Second Quarter 2024 Financial Results

     4 giorni fa

2. ir.ocugen.com › press-releasesPress Releases | Ocugen, Inc.

   ir.ocugen.com › press-releases

   • Cache

   31 lug 2024 · Ocugen, Inc. is a biotechnology company developing novel gene and cell therapies and vaccines for various diseases. Read the latest press releases of its clinical trials, presentations, financial results, and corporate updates.

3. Video

   • 

     4:23

     youtube.com

     Ocugen CEO on distributing Covid-19 vaccines to U.S.

     11 mar. 2021

     51.1K visualizzazioni

   • 

     1:40

     youtube.com

     OCGN Stock (Ocugen Stock) OCGN STOCK PREDICTIONS! OCGN STOCK Analysis ocgn stock news today

     4 gen. 2024

     598 visualizzazioni

   • 

     3:00

     youtube.com

     ocugen stocks breaking news

     25 mag. 2023

     143 visualizzazioni

   Mostra tutto

4. finance.yahoo.com › quote › OCGNOcugen, Inc. (OCGN) Latest Stock News & Headlines - Yahoo Finance

   finance.yahoo.com › quote › OCGN

   • Cache

   3 giorni fa · Get the latest Ocugen, Inc. (OCGN) stock news and headlines to help you in your trading and investing decisions.

5. ocugen.comOcugen Inc. - Patient-Centric Biotechnology

   ocugen.com

   • Cache

   Ocugen is a patient-centric biotech company focused on vaccines, gene and cell therapies. Read the latest news on its COVID-19 vaccine, modifier gene therapy for retinal diseases, and cell therapy for orthopedic disease.

   • 
   • 
   • 
   • 

6. seekingalpha.com › article › 4684807-ocugen-two-gene-therapyOcugen: Two Gene Therapy Data Readouts In 2024 To Drive Value

   seekingalpha.com › article › 4684807-ocugen-two-gene-therapy

   Ocugen is gearing up to report results from the two phase 1/2 studies for the treatment of patients with GA and Stargardt Disease. Check out why OCGN stock is a buy.

   • Autore: Terry Chrisomalis

7. ir.ocugen.com › news-releases › news-release-detailsOcugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical...

   ir.ocugen.com › news-releases › news-release-details

   • Cache

   13 dic 2023 · MALVERN, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in the ArMaDa Phase 1/2 clinical ...

8. ir.ocugen.com › news-releases › news-release-detailsOcugen, Inc. Announces U.S. FDA Clearance of IND Amendment to...

   ir.ocugen.com › news-releases › news-release-details

   • Cache

   8 apr 2024 · Ocugen, a biotechnology company, has received FDA clearance to initiate a Phase 3 clinical trial of OCU400, a gene-agnostic modifier gene therapy for retinitis pigmentosa (RP), a group of rare, genetic disorders that cause vision loss and blindness. OCU400 is the first gene therapy program to enter Phase 3 with a broad RP indication and has orphan drug and RMAT designations.

9. www.ocugen.com › newsNews Feed - Ocugen

   www.ocugen.com › news

   Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa.